Trial Profile
An observational study assessing the effectiveness and safety of pembrolizumab in advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) in a real world
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 28 Nov 2018
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 28 Nov 2018 New trial record
- 14 Nov 2018 Results (n=54) presented at the 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research